Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection
Staphylococcus aureus is the leading cause of nosocomial and community-acquired infections, including soft tissue and skin infections and bacteremia. However, efforts to develop an effective vaccine against S. aureus infections have not been successful. We evaluated serotypes 5 and 8 capsule polysac...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-07-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2017.1304334 |
| _version_ | 1827810026614423552 |
|---|---|
| author | Brian L. Cheng Travis B. Nielsen Paul Pantapalangkoor Fan Zhao Jean C. Lee Christopher P. Montgomery Brian Luna Brad Spellberg Robert S. Daum |
| author_facet | Brian L. Cheng Travis B. Nielsen Paul Pantapalangkoor Fan Zhao Jean C. Lee Christopher P. Montgomery Brian Luna Brad Spellberg Robert S. Daum |
| author_sort | Brian L. Cheng |
| collection | DOAJ |
| description | Staphylococcus aureus is the leading cause of nosocomial and community-acquired infections, including soft tissue and skin infections and bacteremia. However, efforts to develop an effective vaccine against S. aureus infections have not been successful. We evaluated serotypes 5 and 8 capsule polysaccharides (CP) CRM197 conjugates as vaccine candidates in murine models of bacteremia, lethal sepsis, and skin infection. The conjugate vaccines elicited a good antibody response, and active immunization of CP5-CRM or CP8-CRM conjugates protected against staphylococcal bacteremia. In the skin infection model, CP8-CRM but not CP5-CRM protected against dermonecrosis, and CP8-CRM immunization significantly decreased the bacterial burden in the lesion. However, neither CP5-CRM nor CP8-CRM protected against mortality in the lethal sepsis model. The results indicate the capsular vaccines elicit protection against some, but not all, aspects of staphylococcal infection. |
| first_indexed | 2024-03-11T22:47:53Z |
| format | Article |
| id | doaj.art-70b51f87362d4d5a95e92f9c94a2575f |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:47:53Z |
| publishDate | 2017-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-70b51f87362d4d5a95e92f9c94a2575f2023-09-22T08:17:49ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2017-07-011371609161410.1080/21645515.2017.13043341304334Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infectionBrian L. Cheng0Travis B. Nielsen1Paul Pantapalangkoor2Fan Zhao3Jean C. Lee4Christopher P. Montgomery5Brian Luna6Brad Spellberg7Robert S. Daum8University of ChicagoKeck School of Medicine, University of Southern CaliforniaKeck School of Medicine, University of Southern CaliforniaUniversity of ChicagoBrigham and Women's Hospital and Harvard Medical SchoolUniversity of ChicagoKeck School of Medicine, University of Southern CaliforniaKeck School of Medicine, University of Southern CaliforniaUniversity of ChicagoStaphylococcus aureus is the leading cause of nosocomial and community-acquired infections, including soft tissue and skin infections and bacteremia. However, efforts to develop an effective vaccine against S. aureus infections have not been successful. We evaluated serotypes 5 and 8 capsule polysaccharides (CP) CRM197 conjugates as vaccine candidates in murine models of bacteremia, lethal sepsis, and skin infection. The conjugate vaccines elicited a good antibody response, and active immunization of CP5-CRM or CP8-CRM conjugates protected against staphylococcal bacteremia. In the skin infection model, CP8-CRM but not CP5-CRM protected against dermonecrosis, and CP8-CRM immunization significantly decreased the bacterial burden in the lesion. However, neither CP5-CRM nor CP8-CRM protected against mortality in the lethal sepsis model. The results indicate the capsular vaccines elicit protection against some, but not all, aspects of staphylococcal infection.http://dx.doi.org/10.1080/21645515.2017.1304334capsular polysaccharidesstaphylococcus aureusvaccine |
| spellingShingle | Brian L. Cheng Travis B. Nielsen Paul Pantapalangkoor Fan Zhao Jean C. Lee Christopher P. Montgomery Brian Luna Brad Spellberg Robert S. Daum Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection Human Vaccines & Immunotherapeutics capsular polysaccharides staphylococcus aureus vaccine |
| title | Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection |
| title_full | Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection |
| title_fullStr | Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection |
| title_full_unstemmed | Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection |
| title_short | Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection |
| title_sort | evaluation of serotypes 5 and 8 capsular polysaccharides in protection against staphylococcus aureus in murine models of infection |
| topic | capsular polysaccharides staphylococcus aureus vaccine |
| url | http://dx.doi.org/10.1080/21645515.2017.1304334 |
| work_keys_str_mv | AT brianlcheng evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT travisbnielsen evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT paulpantapalangkoor evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT fanzhao evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT jeanclee evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT christopherpmontgomery evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT brianluna evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT bradspellberg evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection AT robertsdaum evaluationofserotypes5and8capsularpolysaccharidesinprotectionagainststaphylococcusaureusinmurinemodelsofinfection |